Now Available:
Download the podcast of Dr. Heffernan's presentation

With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.

MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.

MSK Video Report:


Dr. Jennifer Clay Cather presents "Comorbidities and Quality of Life Issues in Psoriasis" from our 5-part series, "Practical Approaches to Solving Psoriasis Challenges"

Procedures: Skyrocketing Rates of Hip and Knee Replacements May Tax Healthcare System
The US healthcare system should brace itself for an exponential increase in the number of primary and revision joint arthroplasties and their associated costs...

Autoimmunity: PAH Differs in Connective Tissue Diseases
Patients with PAH due to connective tissue disease have more dysfunctional pulmonary capillary endothelium than those with PAH from other causes...

Consumer News: Splints as Good as Plaster Casts for Minor Fractures
Removable splits are a safe, effective, and cheaper option than traditional plaster casts for minor wrist fractures in children, but are easily tampered with...

BioPharm Business: Neurochem to Advance Eprodisate (Kiacta) in Second Phase III Trial for Amyloid A; Marketing Applications Withdrawn in US, EU, and Switzerland
Neurochem (International) Ltd announced that it intends to initiate a second phase III clinical for eprodisate (Kiacta) to obtain market approval for the treatment of amyloid A (AA) because amyloidosis is a life-threatening disease for which there is no specific treatment...

BioPharm Business: Lilly's Forsteo Receives Approval From European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis
Eli Lilly and Co announced that the European Commission has approved a new indication for Forsteo (teriparatide [rDNA origin] injection) for the treatment of sustained, systemic glucocorticoid-induced osteoporosis (GIOP) in adults at increased risk for fracture...

Click here to remove your e-mail address from our mailing list. For questions and comments regarding this newsletter please contact .